Right hepatic lobectomy using the staple technique in 101 patients.
BACKGROUND
Application of linear stapling devices for extrahepatic vascular control in liver surgery has been well-established. However, the technique for use of stapling devices in hepatic parenchymal transection is not well defined.


OBJECTIVE
To describe the safety and efficacy of our technique for use of vascular stapling devices in hepatic parenchymal transection during open right hepatic lobectomy is the purpose of this study.


METHODS
We reviewed our experience with 101 consecutive open right hepatic lobectomies performed by a single surgeon between January 2003 and July 2006, in which vascular staplers were utilized for the parenchymal transection phase.


RESULTS
Of the 101 patients who underwent resection, 53 (52%) were female. The mean age was 58 years. Malignant disease was the indication for resection in the majority of patients (88%). Of those with cancer, 78% (69 of 89) had metastatic colorectal cancer, 6% (5 of 89) had metastatic neuroendocrine tumor, 4% (4 of 89) had hepatocellular carcinoma, 4% (4 of 89) had cholangiocarcinoma, and the remaining 8% were other metastatic cancers. Twelve patients (12%) underwent resection for hepatic adenoma or symptomatic benign disease (FNH or hemangioma). Forty-eight patients (48%) underwent a major ancillary procedure at the time of hepatic resection. Thirty-nine patients (39%) had a nonanatomic wedge resection of a left lobe lesion, 27 patients (27%) had one or more lesions treated with radiofrequency ablation (RFA), and 6 patients (6%) were treated with a synchronous bowel resection. The median total operative time was 336 min (range 155-620 min). A Pringle maneuver for temporary vascular inflow occlusion was utilized in all cases, with a median time of 9 min (range 4-17 min). Ten patients (10%) required blood transfusion during surgery or in the postoperative period. The maximum transfusion was 2 U of packed red blood cells (PRBC) in seven patients and 1 U of PRBC in three patients. The mean nadir postoperative hematocrit was 28.2. All patients with malignant disease had tumor-free margins at the completion of the procedure. The average hospital length of stay was 6.0 days. One patient (1%) developed a clinically significant bile leak requiring a postoperative endoscopic retrograde cholangiography (ERCP). No patient required reoperation. The 30 and 60-day postoperative survival was 100%.


CONCLUSIONS
These findings indicate that application of vascular stapling devices for parenchymal transection in major hepatic resection is a safe technique, with low transfusion requirements and minimal postoperative bile leak. The technique allows for rapid transection of the entire right hepatic lobe in under 10 min. Short video clips of the technique will be demonstrated.
Balaa
Fady K
FK
UPMC Liver Cancer Center, Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Gamblin
T Clark
TC
Tsung
Allan
A
Marsh
J Wallis
JW
Geller
David A
DA
D016063:Blood Loss, Surgical / Q000706:statistics & numerical data; D001803:Blood Transfusion / Q000706:statistics & numerical data; D015179:Colorectal Neoplasms / Q000473:pathology; D005260:Female; D006391:Hemangioma / Q000601:surgery; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D007902:Length of Stay; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D017792:Surgical Stapling
Arch Surg. 1996 Jan;131(1):104-6
8546569
Surgery. 1995 Feb;117(2):140-5
7846617
Colorectal Dis. 2004 May;6(3):165-70
15109380
Am Surg. 2000 Nov;66(11):1037-40
11090014
Am J Surg. 1994 Jul;168(1):49-53
8024098
J Am Coll Surg. 2001 Aug;193(2):210-22
11491452
HPB (Oxford). 2005;7(3):208-13
18333192
J Am Coll Surg. 1994 May;178(5):510-1
8167890
Liver Int. 2007 Feb;27(1):26-39
17241378
Asian J Surg. 2003 Oct;26(4):193-6
14530102
Am J Surg. 1989 Nov;158(5):459-60
2817228
Surg Obes Relat Dis. 2006 Nov-Dec;2(6):669
17138242
Am J Surg. 2004 Feb;187(2):280-4
14769320
J Chir (Paris). 1990 Jun-Jul;127(6-7):356-8
2211893
Surg Endosc. 2004 Jun;18(6):961-3
15108116
Br J Surg. 1991 Jan;78(1):40-1
1998861
J Urol. 1993 Jun;149(6):1437-9; discussion 1439-40
8501782
ANZ J Surg. 2003 Nov;73(11):922-5
14616571
J Am Coll Surg. 1997 Jul;185(1):93-100
9208969
Surg Obes Relat Dis. 2006 Jul-Aug;2(4):431-4
16925374
Am J Surg. 1996 Oct;172(4):358-62
8873530
J Exp Clin Cancer Res. 1999 Sep;18(3):299-303
10606173
Am J Surg. 2005 Jul;190(1):23-9
15972166
Obes Surg. 2003 Dec;13(6):855-9; discussion 860
14738669
Obes Surg. 2006 Dec;16(12):1559-62
17217629
Surg Technol Int. 1998;7:43-7
12721961
J Invest Surg. 1997 Jan-Apr;10(1-2):59-61
9100177
World J Surg. 2006 Mar;30(3):419-30
16467982
Anticancer Res. 2003 Mar-Apr;23(2C):1697-700
12820443
S Afr J Surg. 1992 Jun;30(2):47-8
1519125